CEO of Concert Pharmaceuticals Speaks on how the Company is Applying its Proprietary DCE (Deuterated Chemical Energy) Platform to Modify Drug Molecules with Healthcare Global
CEO of Concert Pharmaceuticals speaks on the company's expansive pipeline of products by applying its proprietary DCE (deuterated chemical entity) Platform to modify specific properties of validated drug molecules.

SAN DIEGO, CA, June 30, 2011 /24-7PressRelease/ -- In a report in Healthcare Digital, Roger Tung, CEO of Concert Pharmaceuticals speaks on the company's expansive pipeline of products by applying its proprietary DCE (deuterated chemical entity) Platform to modify specific properties of validated drug molecules. Concert Pharmaceuticals is using its deuterium chemistry technology to create new and different patentable drugs for the treatment of HIV, pain/spasticity, epilepsy, oncology, diabetic nephropathy, among other ailments.

To date, Concert Pharmaceuticals has more than 90 patent applications for new drug candidates tackling a broad range of therapeutic areas. In addition to a strong management team and Board of Directors, Concert Pharmaceuticals prides its success on the support of venture capitalists and other investors who have supported its research and development and pipeline advancement. The company has raised more than $110 million since its inception.

While Concert Pharmaceuticals currently conducts research and development on several programs, taking an approach that is unique in the industry. "The approach we take is unusual in the fact that we start out with compounds that have very well understood pharmacological activity and are often known to be well tolerated," says Roger Tung, CEO of Concert Pharmaceuticals. "We carry out these processes with an atom called deuterium, which is a relative of hydrogen that, in favorable cases, can change the metabolism of compounds and improve their suitability for the treatment of disease. Our two lead drug candidates treat chronic kidney disease, particularly diabetic nephropathy, and HIV infection."

Read the article here.

About Concert Pharmaceuticals:
Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.

Concert applies its proprietary DCE Platform (deuterated chemical entity platform) to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense.

Press Release Contact Information:

Ashley Koons
Healthcare Global
Marketing Coordinator
5901 Priestly Drive #300
Carlsbad, CA
United States 92008
Voice: 760-827-7800
Website: Visit Our Website